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Introduction 
Cerebral amyloid angiopathy (CAA) is characterised by β-amyloid deposition in small 
to medium arteries, arterioles and capillaries of the cortex and leptomeninges 1. MRI 
features include lobar cerebral microbleeds (best observed using iron sensitive 
sequences), leukoaraiosis, convexity subarachnoid haemorrhage, cortical superficial 
siderosis, and silent acute ischemic lesions, leading to the development of clinical 
(Boston) criteria for in vivo diagnosis.2 CAA can present with intracranial 
haemorrhage, transient neurological episode (amyloid spells), rapidly progressive 
cognitive and neurological decline reflecting CAA related neuroinflammation, as well 
as more insidious cognitive impairment 3. There is considerable evidence that 
Alzheimer’s disease (AD) and CAA are mechanistically linked: 95% of pathology 
proven AD have a degree of CAA pathology 4, ApoE4 is a risk factor for both AD and 
CAA 5 and 23% of patients with sporadic AD have imaging features of CAA5. Given 
that CAA pathology frequently accompanies AD, it may be difficult to unravel the 
relative contribution of each pathology in demented individuals. Whilst acetyl-
cholinesterase inhibitors (AchEI) are widely used in AD, there is little evidence for the 
efficacy in patients with cognitive impairment in CAA, or in mixed disease. Here we 
report three patients with dementia fulfilling criteria for CAA, two with probable and 
one with possible AD, in whom AchEI resulted in marked cognitive improvement.   
Case 1 
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An 81 year-old male was referred with a 3-year history of cognitive decline manifest 
as slowly progressive problems with episodic memory and planning. He had had a 
left posterior intracerebral bleed, histologically proven to be due to CAA, at the age 
of 64. After his stroke he was left with static problems with visual perception function, 
reading, writing and arithmetic.  He had a subsequent haemorrhagic stroke at the 
age of 80 causing dysarthria and dyspraxia but he and his wife were clear that 
cognitive problems had emerged prior to this event and continued to worsen since. 
The MMSE was 11/30; formal neuropsychological evaluation showed evidence for 
parietal dysfunction with weak memory and executive impairment. The MRI showed 
significant white matter change, multiple microhaemorrhages, superficial siderosis, 
and atrophic hippocampi (Figure, panels A,D and G). He was diagnosed with 
probable CAA with supporting pathology (according to Boston criteria) and possible 
AD dementia (according to 2011 NIA guidelines6). He was commenced on Donepezil 
initially 5mg, latterly 10mg daily.  Both he and his wife reported that this resulted in a 
dramatic improvement; he was able to restart playing the piano and cooking (see 
supplemental video). After four months on treatment the MMSE score had 
improved by 11 points to 22/30 (supplemental Table).  
 
Case 2 
A 68 year-old female with a history of ischemic heart disease presented with a 3-
year history of impairments of episodic memory, navigational skills, and behavioural 
change. Examination revealed an MMSE score of 18/30; formal neuropsychological 
evaluation demonstrated impaired visual and verbal memory, impaired naming and 
verbal fluency and weak executive function. MR brain imaging revealed a moderate 
burden of vascular disease, peripheral microhaemorrhages and global atrophy 
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involved the hippocampi (Figure, panels B, E and H). CSF analysis revealed an 
elevated tau/Aβ1-42 ratio (1.77) and phosphorylated tau-181 (98pg/ml, NR 0-61). 
She was diagnosed with Boston criteria probable CAA and probable AD (NIA high 
likelihood) and was commenced on Donepezil.  After two months treatment, the 
MMSE increased by 9 points to 27/30, with significant concomitant improvements in 
activities of daily living. After 20 months of treatment the MMSE was 22/30.    
 
Case 3  
A 66 year old female was referred with a 6 year history of progressive problems with 
vision, numeracy, facial recognition and episodic memory. Examination revealed an 
MMSE of 20/30; formal neuropsychometry demonstrated impaired verbal memory, 
facial recognition and profound visuoperceptual and constructional deficits with some 
evidence for impaired calculation and executive function. MR brain imaging 
demonstrated generalised atrophy (most pronounced posteriorly), multiple cortical 
microhaemorrhages, particularly of the occipital lobes, and confluent white matter 
disease. CSF analysis revealed an elevated tau/Aβ1-42 ratio (1.17) and borderline 
elevation of phosphorylated tau-181 (60pg/ml). She was diagnosed with Boston 
criteria probable CAA and probable AD (NIA high likelihood) and was commenced 
on Donepezil. After 4 months the MMSE had improved to 26/30. After 10 months of 
treatment the MMSE was 27/30.     
 
Discussion 
In AD trials individuals typically improve by 1-2 MMSE points following AchEI 
treatment,7 and so the marked cognitive (11, 9 and 6 MMSE points) and functional 
improvements in these three cases are striking. Most significant improvements were 
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in attention and language. All individuals had several years of cognitive symptoms 
and significant cognitive impairment by the time treatment was commenced, One 
explanation for the marked treatment response might be their degree of impairment: 
despite having moderately severe dementia, the pathological evidence of CAA and 
prior strokes in the first case, and presence of significant white matter changes in the 
second and third, meant that AD had not previously been considered, and none had 
been trialled on an AchEI when less severely affected. Another possibility is that the 
combination of CAA and AD pathology is associated with a more pronounced 
cholinergic deficit, predicting a greater response to AchEI treatment. These cases 
demonstrate the difficulties in ascribing cognitive deficits to CAA or AD pathology, 
and suggest that AchEI treatment should be considered in patients with CAA and 
cognitive decline. 
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Figure. MRI images for subjects 1 (Panels A,D,G), 2 (Panels B,E,H) and 3 (Panels 
C,F,I)  
  
Volumetric T1 MRI showing significant hippocampal atrophy in subject 1 (A) and 
generalised atrophy in Subjects 2 (B) and 3 (C); T2 fluid attenuated inversion 
recovery (FLAIR) MRI showing established cortical stroke in subject 1 (C) and deep 
white matter and periventricular high signal in subjects 1 (C), 2 (D) and 3 (F). 
Susceptibility weighted image (SWI) MRI sequence showing peripheral microbleeds 
in subjects 1 (E), 2(F) and posterior microbleeds with a posterior predominance in 
3(I).  
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Supplemental video 
 
The individual described in case 1 and his wife describe an improvement in 
symptoms 3 months after starting AchEI donepezil (10mg). 
 
Supplemental Table  
 
Mini mental state examination scores before and after treatment with cholinesterase 
inhibitors.   
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MMSE Domain  Case Pre-treatment  Post 
Treatment 
Orientation (max 10) 1 4 10 
 2 5 9 
 3 10 10 
Registration (max 3)  1 3 3 
 2 3 3 
 3 3 3 
Attention and 
Calculation (max 5) 
1  0 1 
 2 3  5 
 3 2 5 
Recall (max 3)  1 1 0 
 2 0 1 
 3 1 2 
Language (max 8) 1 3 7 
 2 6 8 
 3 3 6 
Copying (max 1)   1 0 1 
 2 1 1 
 3 1 0 
Total 1 11 22 
 2 18 27 
 3 20 26 
 
Highlights 
 
 CAA pathology frequently accompanies AD pathology 
 CAA and AD pathology are likely to be mechanistically linked 
 Individuals with AD pathology alone typically benefit from a modest cognitive 
improvement with AchEI (~2 MMSE points) 
 We observe a striking cognitive improvement in 3 individuals with co-existing 
CAA and AD when treated with AchEI 
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